A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
about
Second-line chemotherapy for locally advanced or metastatic small cell lung cancerMulti-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerWeekly dose-dense cisplatin-epirubicin-paclitaxel administration with granulocyte colony-stimulating factor support does not substantially improve prognosis in extensive disease small-cell lung cancer. A SICOG phase II study.Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer.Treatment options for small cell lung cancer - do we have more choice?Small cell lung cancer: therapies and targetsExtensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms.Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802).Lung cancer--where are we today? Current advances in staging and nonsurgical treatment.Chemotherapy for small cell lung cancer: a comprehensive reviewFirst-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma.A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group.Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.Combination of three cytotoxic agents in small-cell lung cancer.Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancerPemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial.Topotecan for the treatment of small-cell lung cancer.Radiochemotherapy in small-cell lung cancer.Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.Cisplatin plus etoposide versus other platin-based regimens for patients with extensive small-cell lung cancer: a systematic review and meta-analysis of randomised, controlled trials.Medical treatment of small cell lung cancer: state of the art and new development.Implications of therapy-induced selective autophagy on tumor metabolism and survival.A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.Eribulin inhibits the growth of small cell lung cancer cell lines alone and with radiotherapy.
P2860
Q24241040-99F63812-AF25-4C7F-B3FB-DD88D34058C6Q33361868-0076F5E4-47B3-46CA-89B7-C6B8CE6406C3Q33367263-B743FE47-3AC2-4E4E-98F4-2856CA375B1AQ33425887-5EAE58CC-605F-467A-8A46-4E0D5CCF73ACQ33723735-0CF7D310-9604-4C50-B38A-B62FCD33361BQ34250859-1856D5D5-7DF8-4D2E-B6EF-F6A2E106467AQ34252309-0DEDF11D-7CE0-41A9-B986-7BFE59A6B281Q34736580-1DA3CACF-7B17-4D1F-A44A-0C4958F18D5EQ34982142-77AD1885-8C8F-45F7-88BE-CE9445B5258AQ35569379-B3E3F58D-9B26-4654-9D8E-19CF5107DAEBQ36352317-97538885-A9AF-4B5C-AAA7-FD3FC8131D52Q36482519-3B74F6B4-FCD2-4AFA-854C-624C1E3FEAB5Q36484581-118A7418-AC31-4888-A4F6-976A52134050Q36566248-DF6BF9A5-793B-41DE-AD13-D003C5AD15DBQ36612607-875C0B9D-DBD3-4F49-AFEE-12CE58D7A1EFQ36817105-0AADEFF7-5A4F-4463-A246-9733EF3D78E3Q36842752-451133D5-6243-4AE8-90C2-7E5EA760201BQ37614569-5A14D0B9-ADA5-4090-B0FA-4858AD14382CQ37698957-C0DEB977-D7BF-40C3-B91B-F25E6A8FB177Q38005201-D4E78E46-860E-42F2-8196-799A2AC7E018Q38125489-9CEB35D5-8744-409A-B597-DBF5373F9BBFQ42541156-886581B0-E0EF-4ABB-8D81-3A730C997836Q45217486-EBF96C80-8B68-49D8-9DC1-6EA72A94A405Q48374393-E34301E4-6145-4BA2-A8ED-6B7801DED218Q51584781-E7003DAB-471A-44E2-8098-61FF111DF290Q52639681-14C9E3F8-CC3F-4324-B709-9E57F220786E
P2860
A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A multicenter randomized clini ...... s with small-cell lung cancer.
@ast
A multicenter randomized clini ...... s with small-cell lung cancer.
@en
A multicenter randomized clini ...... s with small-cell lung cancer.
@nl
type
label
A multicenter randomized clini ...... s with small-cell lung cancer.
@ast
A multicenter randomized clini ...... s with small-cell lung cancer.
@en
A multicenter randomized clini ...... s with small-cell lung cancer.
@nl
prefLabel
A multicenter randomized clini ...... s with small-cell lung cancer.
@ast
A multicenter randomized clini ...... s with small-cell lung cancer.
@en
A multicenter randomized clini ...... s with small-cell lung cancer.
@nl
P2093
P356
P1433
P1476
A multicenter randomized clini ...... s with small-cell lung cancer.
@en
P2093
C Kouroussis
D Mavroudis
E Papadakis
Greek Lung Cancer Cooperative Group
J Jordanoglou
J Stavrakakis
J Vlachonicolis
M Agelidou
M Veslemes
P304
P356
10.1023/A:1011131303391
P577
2001-04-01T00:00:00Z